<p>黑钻石治疗公司（NASDAQ:BDTX - 获取免费报告）在周三发布给投资者的报告中，被 Guggenheim 的股票研究人员从 “买入” 评级下调至 “中性” 评级，MarketBeat 报道。</p>
<p>其他股票研究分析师最近也对该股票发布了研究报告。HC Wainwright 在 8 月 11 日的研究报告中将黑钻石治疗公司的目标股价从 12.00 美元下调至 10.00 美元，并给予该公司 “买入” 评级。Stifel Nicolaus 在 10 月 15 日的报告中开始覆盖黑钻石治疗公司，给予 “买入” 评级和 8.00 美元的目标价。Zacks Research 在 10 月 10 日的研究报告中将黑钻石治疗公司的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在周一的报告中重申了对黑钻石治疗公司股票的 “卖出（d+）” 评级。最后，Piper Sandler 在 11 月 18 日的报告中开始覆盖黑钻石治疗公司，给予 “增持” 评级和 9.00 美元的目标价。一位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，黑钻石治疗公司的平均评级为 “适度买入”，共识目标价为 9.50 美元。</p>
<p><strong>查看我们对 BDTX 的最新分析</strong></p>
<h2>黑钻石治疗公司的价格表现</h2>
<p>黑钻石治疗公司的股票在周三的交易中下跌 0.83 美元，报 2.62 美元。该公司的股票交易量为 7,880,188 股，而其平均交易量为 1,694,199 股。该公司的市值为 1.492 亿美元，市盈率为 7.31，贝塔值为 3.33。该股票的 50 日移动平均价为 3.90 美元，200 日移动平均价为 3.11 美元。黑钻石治疗公司的 12 个月低点为 1.20 美元，12 个月高点为 4.94 美元。</p>
<p>黑钻石治疗公司（NASDAQ:BDTX - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，超出市场共识预期的-0.22 美元，超出幅度为 0.07 美元。股票分析师预计黑钻石治疗公司在本年度将发布-1.3 的每股收益。</p>
<h2>黑钻石治疗公司的机构交易</h2>
<p>一些大型投资者最近增加或减少了对 BDTX 的持股。R Squared Ltd 在第二季度以 25,000 美元的估值收购了黑钻石治疗公司的新股份。Cerity Partners LLC 在第二季度以约 26,000 美元的估值购买了黑钻石治疗公司的新股份。Hudson Bay Capital Management LP 在第二季度以约 26,000 美元的估值购买了黑钻石治疗公司的新股份。Wealth Enhancement Advisory Services LLC 在第二季度以约 28,000 美元的估值收购了黑钻石治疗公司的新股份。最后，American Century Companies Inc.在第二季度以约 30,000 美元的估值购买了黑钻石治疗公司的新股份。机构投资者和对冲基金持有该公司 95.47% 的股票。</p>
<h2>关于黑钻石治疗公司</h2>
<p>（获取免费报告）</p>
<p>黑钻石治疗公司是一家临床阶段的肿瘤医学公司，专注于为具有基因定义肿瘤的患者发现和开发 MasterKey 疗法。该公司的主要产品候选药物是 BDTX-1535，一种能够穿透大脑的表皮生长因子受体 MasterKey 抑制剂，目前正在进行针对表皮生长因子受体突变型非小细胞肺癌的二期临床试验，以及针对胶质母细胞瘤的一期临床试验。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比黑钻石治疗公司更好</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>NASA 呼叫，Plug 回答：氢气的转折点？</li>
<li>什么是股息？购买最佳股息股票</li>
<li>2026 年会是 Costco 的转折点吗？</li>
<li>为什么除息日对投资者来说重要？</li>
<li>人工智能热潮推动意想不到的股票飙升——这三家公司正在大获其利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在黑钻石治疗公司吗？</h2>
<p>在你考虑黑钻石治疗公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而黑钻石治疗公司并不在名单上。</p>
<p>虽然黑钻石治疗公司目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BDTX

<p>Guggenheim 将 Black Diamond Therapeutics（NASDAQ:BDTX）的评级从 “买入” 下调至 “中性”。其他分析师的评级各不相同，有的下调评级，有的则维持 “买入” 评级。多位分析师调整了该股的目标价格，该公司的股票最近交易价格为 2.62 美元。机构投资者对该公司表现出兴趣。Black Diamond Therapeutics 专注于开发针对基因定义肿瘤的疗法</p>

<p>Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) was downgraded by equities researchers at Guggenheim from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a note issued to investors on Wednesday, MarketBeat reports.</p>
<div class="lb-trans"><p>黑钻石治疗公司（NASDAQ:BDTX - 获取免费报告）在周三发布给投资者的报告中，被 Guggenheim 的股票研究人员从 “买入” 评级下调至 “中性” 评级，MarketBeat 报道。</p>
</div><p>Other equities research analysts also recently issued research reports about the stock. HC Wainwright lowered their price objective on shares of Black Diamond Therapeutics from $12.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, August 11th. Stifel Nicolaus began coverage on Black Diamond Therapeutics in a report on Wednesday, October 15th. They set a &#34;buy&#34; rating and a $8.00 target price for the company. Zacks Research downgraded Black Diamond Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 10th. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Black Diamond Therapeutics in a report on Monday. Finally, Piper Sandler assumed coverage on Black Diamond Therapeutics in a report on Tuesday, November 18th. They set an &#34;overweight&#34; rating and a $9.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Black Diamond Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.50.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该股票发布了研究报告。HC Wainwright 在 8 月 11 日的研究报告中将黑钻石治疗公司的目标股价从 12.00 美元下调至 10.00 美元，并给予该公司 “买入” 评级。Stifel Nicolaus 在 10 月 15 日的报告中开始覆盖黑钻石治疗公司，给予 “买入” 评级和 8.00 美元的目标价。Zacks Research 在 10 月 10 日的研究报告中将黑钻石治疗公司的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在周一的报告中重申了对黑钻石治疗公司股票的 “卖出（d+）” 评级。最后，Piper Sandler 在 11 月 18 日的报告中开始覆盖黑钻石治疗公司，给予 “增持” 评级和 9.00 美元的目标价。一位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，黑钻石治疗公司的平均评级为 “适度买入”，共识目标价为 9.50 美元。</p>
</div><p><strong>View Our Latest Analysis on BDTX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BDTX 的最新分析</strong></p>
</div><h2>Black Diamond Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>黑钻石治疗公司的价格表现</h2>
</div><p>Shares of Black Diamond Therapeutics stock traded down $0.83 during trading hours on Wednesday, hitting $2.62. The company's stock had a trading volume of 7,880,188 shares, compared to its average volume of 1,694,199. The company has a market capitalization of $149.20 million, a PE ratio of 7.31 and a beta of 3.33. The stock has a 50 day moving average of $3.90 and a 200 day moving average of $3.11. Black Diamond Therapeutics has a 12 month low of $1.20 and a 12 month high of $4.94.</p>
<div class="lb-trans"><p>黑钻石治疗公司的股票在周三的交易中下跌 0.83 美元，报 2.62 美元。该公司的股票交易量为 7,880,188 股，而其平均交易量为 1,694,199 股。该公司的市值为 1.492 亿美元，市盈率为 7.31，贝塔值为 3.33。该股票的 50 日移动平均价为 3.90 美元，200 日移动平均价为 3.11 美元。黑钻石治疗公司的 12 个月低点为 1.20 美元，12 个月高点为 4.94 美元。</p>
</div><p>Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. Equities analysts expect that Black Diamond Therapeutics will post -1.3 EPS for the current year.</p>
<div class="lb-trans"><p>黑钻石治疗公司（NASDAQ:BDTX - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，超出市场共识预期的-0.22 美元，超出幅度为 0.07 美元。股票分析师预计黑钻石治疗公司在本年度将发布-1.3 的每股收益。</p>
</div><h2>Institutional Trading of Black Diamond Therapeutics</h2>
<div class="lb-trans"><h2>黑钻石治疗公司的机构交易</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in BDTX. R Squared Ltd acquired a new position in Black Diamond Therapeutics in the 2nd quarter valued at $25,000. Cerity Partners LLC bought a new stake in shares of Black Diamond Therapeutics in the second quarter valued at about $26,000. Hudson Bay Capital Management LP bought a new stake in shares of Black Diamond Therapeutics in the second quarter valued at about $26,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Black Diamond Therapeutics in the second quarter valued at about $28,000. Finally, American Century Companies Inc. bought a new position in Black Diamond Therapeutics during the second quarter worth about $30,000. Institutional investors and hedge funds own 95.47% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对 BDTX 的持股。R Squared Ltd 在第二季度以 25,000 美元的估值收购了黑钻石治疗公司的新股份。Cerity Partners LLC 在第二季度以约 26,000 美元的估值购买了黑钻石治疗公司的新股份。Hudson Bay Capital Management LP 在第二季度以约 26,000 美元的估值购买了黑钻石治疗公司的新股份。Wealth Enhancement Advisory Services LLC 在第二季度以约 28,000 美元的估值收购了黑钻石治疗公司的新股份。最后，American Century Companies Inc.在第二季度以约 30,000 美元的估值购买了黑钻石治疗公司的新股份。机构投资者和对冲基金持有该公司 95.47% 的股票。</p>
</div><h2>About Black Diamond Therapeutics</h2>
<div class="lb-trans"><h2>关于黑钻石治疗公司</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.</p>
<div class="lb-trans"><p>黑钻石治疗公司是一家临床阶段的肿瘤医学公司，专注于为具有基因定义肿瘤的患者发现和开发 MasterKey 疗法。该公司的主要产品候选药物是 BDTX-1535，一种能够穿透大脑的表皮生长因子受体 MasterKey 抑制剂，目前正在进行针对表皮生长因子受体突变型非小细胞肺癌的二期临床试验，以及针对胶质母细胞瘤的一期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Black Diamond Therapeutics</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>NASA Calls, Plug Answers: A Turning Point for Hydrogen?</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Will 2026 Mark a Turnaround for Costco?</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>The AI Boom Is Powering an Unexpected Stock Surge—And These 3 Companies Are Winning Big</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比黑钻石治疗公司更好</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>NASA 呼叫，Plug 回答：氢气的转折点？</li>
<li>什么是股息？购买最佳股息股票</li>
<li>2026 年会是 Costco 的转折点吗？</li>
<li>为什么除息日对投资者来说重要？</li>
<li>人工智能热潮推动意想不到的股票飙升——这三家公司正在大获其利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Black Diamond Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在黑钻石治疗公司吗？</h2>
</div><p>Before you consider Black Diamond Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑黑钻石治疗公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而黑钻石治疗公司并不在名单上。</p>
</div><p>While Black Diamond Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然黑钻石治疗公司目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Guggenheim 下调了 Black Diamond Therapeutics（NASDAQ:BDTX）的股票评级